Concepedia

Marie-Pierre L. Collin

ML

Statistics

Publications

4

Citations

205

H-Index

4

Active since

2014

Affiliations

Bayer (Germany)(Current)

Marie-Pierre L. Collin is an author at Bayer (Germany) specializing in pharmacology, fibroblast growth factor receptor signaling, and drug discovery.

ORCID

Publications per year

2014–2020

4

Publications

4

Rogaratinib: A potent and selective pan‐FGFR inhibitor with broad antitumor activity in FGFR‐overexpressing preclinical cancer models

Sylvia Grünewald, Oliver Politz, Sebastian Bender et al. · International Journal of Cancer · 2019 · 101 citations · Full text

, , +16

Discovery of Rogaratinib (BAY 1163877): a pan‐FGFR Inhibitor

Marie-Pierre L. Collin, Mario Lobell, Walter Hübsch et al. · ChemMedChem · 2018 · 62 citations

, , +17

Structure–Permeability Relationship of Semipeptidic Macrocycles—Understanding and Optimizing Passive Permeability and Efflux Ratio

Antoine Le Roux, Émilie Blaise, Pierre‐Luc Boudreault et al. · Journal of Medicinal Chemistry · 2020 · 32 citations

, , +17

Abstract 1739: Preclinical profile of BAY 1163877 - a selective pan-FGFR inhibitor in phase 1 clinical trial

Mélanie Héroult, Peter Ellinghaus, Christian Sieg et al. · Cancer Research · 2014 · 10 citations

, , +16

1–4 of 4